The purpose of this study is to proof increasing patient satisfaction and preservation of quality of life in patients with Morbus Fabry disease receiving their Enzyme Replacement Therapy with Replagal (Agalsidase alfa) at home compared to receiving the infusions at the clinic or at doctor's practice.
Study Type
OBSERVATIONAL
Enrollment
127
Landeskrankenhaus Bregenz
Bregenz, Austria
Patient satisfaction estimated on a 10-ary Likert scale
Time frame: comparison of baseline to 12 months value
Number (per infusion) and severity of infusion-related side effects
Time frame: baseline compared to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
LKH-Universitätsklinikum Graz
Graz, Austria
Paracelsus Medizinische Privatuniversität Salzburg
Salzburg, Austria
Universitätsklinik für Innere Medizin III
Vienna, Austria
Universitätsklinik für Kinder- und Jugendheilkunde
Vienna, Austria
Charité - Universitätsmedizin Berlin
Berlin, Germany
Klinik II für Innere Medizin
Cologne, Germany
Med. Versorgungszentrum Dialyse-Centrum Cuxhaven
Cuxhaven, Germany
Alfried-Krupp-Krankenhaus Rüttenscheid
Essen, Germany
MVZ Immunologie am Krankenhaus Sachsenhausen
Frankfurt, Germany
...and 12 more locations